Hims & Hers reported Q4 and full-year 2025 earnings after the close on Monday, February 23, 2026. The numbers showed continued scale and improving profitability, but the near-term guidance (especially Q1) came in weak versus expectations—driving an immediate negative market reaction.
What Hims & Hers reported (Q4 2025)
Revenue: $617.8M, up 28% year over year (slightly below the Street’s ~$619M area in several recaps).
Earnings: Coverage broadly described a clear EPS beat, commonly cited as $0.08 per share (methodology can vary by outlet, but directionally it was better than expected).
Subscribers: ~2.5M, up 13% YoY—suggesting the core subscription engine is still expanding.
Full-year 2025: The company’s materials emphasize ~$2.35B revenue (+59% YoY), $128M net income, and $318M adjusted EBITDA.
Related articles
Read-through: This wasn’t an operational “blow-up.” Growth remains strong, but the bar for forward momentum is high—especially in the weight-loss category.
The real issue: Q1 2026 guidance missed by a lot
Q1 2026 revenue guide: $600M–$625M versus a widely cited consensus around $653M.
Q1 2026 adjusted EBITDA guide: $35M–$55M—called out by analysts as particularly soft, reinforcing the idea that near-term margins will be pressured.
That combination (lower near-term growth + weaker near-term profitability) is why investors looked past the Q4 beat.
Why the outlook softened: GLP-1 headwinds + spending ramp
1) Weight-loss (GLP-1) disruption is creating volatility
Reuters highlighted a ~$65M impact tied to legal changes requiring more personalized prescriptions for weight-loss drugs. The broader theme: compounded GLP-1 offerings have become a regulatory/legal battleground, and that uncertainty is now being reflected in guidance conservatism.
Barron’s also pointed to ongoing legal/regulatory scrutiny related to compounded GLP-1s, which investors interpret as risk to a meaningful revenue stream.
2) Higher investment intensity (marketing + expansion)
Multiple writeups framed the quarter as “mixed” largely because the company is leaning into growth investments (marketing, new initiatives, expansion), which tends to compress margins in the short run—and shows up most clearly in the Q1 EBITDA range.
Market reaction: Hims & Hers shares
Reuters reported the stock dropped about 7% in after-hours trading following the guidance.
As of the latest available quote today (Feb 24, 2026), HIMS is around $15.51.
Side narrative: the Eucalyptus deal added “execution risk” to the mix
In parallel, Hims is pursuing international expansion via its agreement to acquire Eucalyptus in a transaction valued up to $1.15B (with cash at close plus deferred/earn-out components). Strategically, it broadens geography and product reach; tactically, it adds integration and capital-allocation scrutiny—especially when near-term guidance is already under pressure.
Takeaway
The market didn’t punish Hims for Q4 performance as much as it punished the message about the next quarter: Q1 revenue and EBITDA guidance were materially below expectations, with management pointing to GLP-1 regulatory/legal friction and investment spending as key factors. In growth stocks, that near-term reset tends to dominate the tape.
FAQ
Did Hims “miss” earnings?
Most recaps described an EPS beat (often cited as ~$0.08), while revenue was slightly below expectations.
Why would the stock drop if EPS beat?
Because forward guidance (Q1 revenue and EBITDA) came in well below consensus, signaling a near-term slowdown and/or margin pressure.
What specifically drove the Q1 revenue shortfall narrative?
A key cited factor was a ~$65M impact tied to legal changes around personalized prescribing for weight-loss drugs, plus broader GLP-1 uncertainty.
Is the Eucalyptus acquisition part of current guidance?
Coverage indicates the deal is a major strategic move, but it has also been framed as an added variable for investors (integration/execution), particularly alongside a weak Q1 guide.
Disclaimer
This is informational commentary, not investment advice. Figures can differ across sources due to GAAP vs. non-GAAP definitions and timing of updates. Markets are volatile; consider reviewing the company’s filings and consulting a qualified professional before making investment decisions.
